Immunologic Monitoring to Personalize Immunosuppression After Liver Transplant

Andrew Zhu; Alexandra Leto; Abraham Shaked; Brendan Keating

doi:10.1016/j.gtc.2018.01.003

Immunologic Monitoring to Personalize Immunosuppression After Liver Transplant

Gastroenterol Clin North Am. 2018 Jun;47(2):281-296. doi: 10.1016/j.gtc.2018.01.003.

Authors

Andrew Zhu¹, Alexandra Leto¹, Abraham Shaked², Brendan Keating¹

Affiliations

¹ Division of Transplantation, Department of Surgery, Penn Transplant Institute, The University of Pennsylvania, 3400 Spruce Street, Two Dulles Pavilion, Philadelphia, PA 19104, USA.
² Division of Transplantation, Department of Surgery, Penn Transplant Institute, The University of Pennsylvania, 3400 Spruce Street, Two Dulles Pavilion, Philadelphia, PA 19104, USA. Electronic address: abraham.shaked@uphs.upenn.edu.

PMID: 29735024
DOI: 10.1016/j.gtc.2018.01.003

Abstract

Although immunosuppressive drugs have enhanced patient outcomes in transplantation, the liver transplant community has made significant research efforts into the discovery of more accurate and precise methods of posttransplant monitoring and diagnosing. Current research in biomarkers reveals many promising approaches.

Keywords: Biomarker monitoring; Immunosuppression; Liver transplantation; Personalization; Pharmacogenetics.

Publication types

Review

MeSH terms

Biomarkers / blood
Graft Rejection / immunology*
Humans
Immunosuppression Therapy* / adverse effects
Immunosuppression Therapy* / methods
Immunosuppressive Agents / therapeutic use*
Liver Transplantation*
MicroRNAs / blood*
Pharmacogenetics
Precision Medicine*
T-Lymphocytes, Regulatory

Substances

Biomarkers
Immunosuppressive Agents
MicroRNAs